304 related articles for article (PubMed ID: 20705936)
21. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
[TBL] [Abstract][Full Text] [Related]
23. Origin of ovarian cancer may have implications for screening.
Tuma RS
J Natl Cancer Inst; 2010 Jan; 102(1):11-3. PubMed ID: 20023201
[No Abstract] [Full Text] [Related]
24. Ovarian cancer screening: Current status and future directions.
Nash Z; Menon U
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169
[TBL] [Abstract][Full Text] [Related]
25. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
26. Update on ovarian cancer screening.
Munkarah A; Chatterjee M; Tainsky MA
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
[TBL] [Abstract][Full Text] [Related]
27. Advances in the early detection of ovarian cancer: How to hear the whispers early.
Cesario S
Nurs Womens Health; 2010 Jun; 14(3):222-34. PubMed ID: 20579298
[No Abstract] [Full Text] [Related]
28. CA-125: a biomarker put to the test.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
[No Abstract] [Full Text] [Related]
29. Clinical evaluations of a new ovarian cancer marker, COX-1.
Lee G; Ng HT
Int J Gynaecol Obstet; 1995 Jul; 49 Suppl():S27-32. PubMed ID: 7589737
[TBL] [Abstract][Full Text] [Related]
30. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
[TBL] [Abstract][Full Text] [Related]
31. From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers.
Yekula A; Muralidharan K; Kang KM; Wang L; Balaj L; Carter BS
Methods; 2020 May; 177():58-66. PubMed ID: 32061674
[TBL] [Abstract][Full Text] [Related]
32. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
33. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
34. [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy].
Mrochem-Kwarciak J; Mrochen-Domin I; Wojcieszek A; Deja R; Chmura A; Masłyk B; Nowara E; Kaleta B; Kołosza Z; Bartnik W
Ginekol Pol; 2011 Dec; 82(12):911-7. PubMed ID: 22384627
[TBL] [Abstract][Full Text] [Related]
35. Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
Pisal N; Sindos M; Singer A
J Natl Cancer Inst; 2003 Feb; 95(4):331; author reply 331-2. PubMed ID: 12591991
[No Abstract] [Full Text] [Related]
36. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
37. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
38. Elevated ovarian cancer marker (CA-125) in cirrhotic patients with intractable ascites.
Zamir D; Jarchovsky J; Singer C; Weiner P
J Clin Gastroenterol; 1998 Sep; 27(2):154-5. PubMed ID: 9754780
[No Abstract] [Full Text] [Related]
39. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
Selman AE; Copeland LJ
Curr Oncol Rep; 1999 Sep; 1(1):71-6. PubMed ID: 11122801
[TBL] [Abstract][Full Text] [Related]
40. Cancer biomarkers: knowing the present and predicting the future.
Chatterjee SK; Zetter BR
Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
